Colorectal Cancer held the largest share of the liver metastases treatment market in 2025, reflecting its established role as a major source of secondary liver involvement that routinely enters structured treatment pathways. This leadership is maintained through the consistent clinical need for liver-directed and systemic treatment approaches in colorectal cancer cases where hepatic spread is a common management challenge. The liver metastases treatment market continues to see Colorectal Cancer remain dominant because treatment decision-making in this segment is well integrated into oncology practice, supporting steady patient flow into intervention and follow-up care.

Breast Cancer is the fastest-growing segment in the liver metastases treatment market as treatment demand is expanding alongside broader clinical attention to metastatic disease management and more active surveillance of disease progression to the liver. Its momentum relative to other primary cancer segments is aided by evolving therapeutic requirements in patients who need sustained, often sequential treatment strategies after liver involvement is identified. As a result, the liver metastases treatment market is seeing faster growth from Breast Cancer cases where ongoing management complexity is translating into rising treatment utilization.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Specialty Pharmacies (Fastest-Growing Segment)

Hospital Pharmacies accounted for a 58.27% share of the liver metastases treatment market in 2025, aided by their central role in dispensing and managing therapies used within hospital-based oncology care. Their leadership reflects the fact that many liver metastases treatment regimens are closely tied to specialist supervision, coordinated inpatient or outpatient procedures, and direct clinician oversight, all of which favor hospital pharmacy channels. In the liver metastases treatment market, this channel remains dominant because it is embedded in the care setting where diagnosis, treatment administration, and monitoring are often tightly connected.

Specialty Pharmacies are emerging as the fastest-growing channel in the liver metastases treatment market because they are better aligned with the growing need for focused handling of complex oncology therapies outside traditional hospital dispensing models. Their growth is being influenced by practical care delivery shifts that require closer patient support, reimbursement coordination, and management of specialized medications over longer treatment durations. Compared with broader dispensing channels, Specialty Pharmacies are gaining momentum in the liver metastases treatment market by addressing the operational demands of increasingly tailored cancer treatment pathways.